Synergistic Effects of NOTCH/γ-Secretase Inhibition and Standard of Care Treatment Modalities in Non-small Cell Lung Cancer Cells

by Venus Sosa Iglesias, Jan Theys, Arjan J. Groot, Lydie M. O. Barbeau, Alyssa Lemmens, Ala Yaromina, Mario Losen, Ruud Houben, Ruud Houben, Ludwig Dubois, Marc Vooijs, Marc Vooijs
Published 2018-11-01

Prognostic Role of Hypoxia-Inducible Factor-2α Tumor Cell Expression in Cancer Patients: A Meta-Analysis

by Eloy Moreno Roig, Ala Yaromina, Ruud Houben, Arjan J. Groot, Ludwig Dubois, Marc Vooijs
Published 2018-06-01

Are patients with stage III non-small cell lung cancer treated with chemoradiotherapy at risk for cardiac events? Results from a retrospective cohort study

by Juliette Degens, D De Ruysscher, Ruud Houben, Bastiaan Kietselaer, Gerben Bootsma, Lizza Hendriks, Ellen Huijbers, Annemie Schols, Anne-Marie C Dingemans
Published 2020-09-01

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials

by Linda Spiegelberg, Ruud Houben, Raymon Niemans, Dirk de Ruysscher, Ala Yaromina, Jan Theys, Christopher P. Guise, Jeffrey B. Smaill, Adam V. Patterson, Philippe Lambin, Ludwig J. Dubois
Published 2019-02-01